Sarepta Therapeutics case study

Why Sarepta Therapeutics, Inc. (SRPT) 12% on 09/06/17? Sarepta Therapeutics, Inc. (SRPT) jumped 12% as a result of Bullish news signal: Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced muscle biopsy results from its 4053-101 study, a Phase 1/2 [...]

By | September 6th, 2017|case studies, Uncategorized|Comments Off on Sarepta Therapeutics case study

Iovance Biotherapeutics case study

Why Iovance Biotherapeutics, Inc. (IOVA) 10% on 09/01/17? Iovance Biotherapeutics, Inc. (IOVA) jumped 10% as a result of Bullish news signal: Iovance Biotherapeutics, Inc. a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LN-144, the [...]

By | September 1st, 2017|case studies, Uncategorized|Comments Off on Iovance Biotherapeutics case study

Shoe Carnival case study

Why Shoe Carnival, Inc. (SCVL) 22% on 08/31/17? Shoe Carnival, Inc. (SCVL) jumped 22% as a result of Bullish news signal:  Shoe Carnival shares rallied 22% to $20.03 as the company reported second-quarter net income of $3.9 million, or 24 cents a share, compared to $4.1 million, or 22 cents a share, in the year-ago [...]

By | August 31st, 2017|case studies, Uncategorized|Comments Off on Shoe Carnival case study

Teva Pharmaceutical case study

Why Teva Pharmaceutical Industries Limited (TEVA) 3% on 08/31/17? Teva Pharmaceutical jumped 3% as a result of Bullish news signal: Teva Pharmaceutical Industries Ltd.  today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO® (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. AUSTEDO® was previously approved for the treatment of chorea associated [...]

By | August 31st, 2017|case studies, Uncategorized|Comments Off on Teva Pharmaceutical case study

Mazor Robotics case study

Why Mazor Robotics Ltd. (MZOR) 9% on 08/30/17? Mazor Robotics Ltd. (MZOR) jumped 9% as a result of Bullish news signal: Shares of Mazor Robotics Ltd. jumped as the company announced it has entered the next phase of its strategic partnership with Medtronic PLC earlier than planned. Medtronic will assume an exclusive worldwide distribution of [...]

By | August 30th, 2017|case studies, Uncategorized|Comments Off on Mazor Robotics case study

AeroVironment case study

Why AeroVironment, Inc. (AVAV) 14% on 08/30/17? AeroVironment, Inc. (AVAV) jumped 14% as a result of Bullish news signal: AeroVironment Inc. shares surged 14% after the drone maker's quarterly results topped Wall Street estimates. “The AeroVironment team successfully executed our plan in the first quarter, delivering $43.8 million in revenue, a 21 percent increase over first quarter [...]

By | August 30th, 2017|case studies, Uncategorized|Comments Off on AeroVironment case study

Abeona Therapeutics case study

Why Abeona Therapeutics Inc. (ABEO) 18% on 08/29/17? Abeona Therapeutics Inc. (ABEO) jumped 18% as a result of Bullish news signal: Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation status to [...]

By | August 29th, 2017|case studies, Uncategorized|Comments Off on Abeona Therapeutics case study

ImmunoGen case study

Why ImmunoGen, Inc. (IMGN) 18% on 08/29/17? ImmunoGen, Inc. (IMGN) jumped 18% as a result of Bullish news signal: ImmunoGen Inc. has decided to partner with Jazz Pharmaceuticals PLC for the development and commercialization of two early-stage, hematology-related antibody-drug conjugate (ADC) programs, as well as an additional program to be designated during the term of [...]

By | August 29th, 2017|case studies, Uncategorized|Comments Off on ImmunoGen case study

Tandem Diabetes case study

Why Tandem Diabetes Care, Inc. (TNDM) 49% on 08/28/17? Tandem Diabetes Care, Inc. (TNDM) jumped 49% as a result of Bullish news signal: Tandem Diabetes Care®, Inc, a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced U.S. Food and Drug Administration (FDA) approval and commercial [...]

By | August 28th, 2017|case studies, Uncategorized|Comments Off on Tandem Diabetes case study

Kite Pharma case study

Why Kite Pharma, Inc. (KITE) 28% on 08/28/17? Kite Pharma, Inc. (KITE) jumped 28% as a result of Bullish news signal: Gilead Sciences will pay $11.9 billion in cash to buy Kite Pharma and plant a stake in an emerging area of cancer treatments that train a patient's immune cells to attack tumors. Kite's portfolio [...]

By | August 28th, 2017|case studies, Uncategorized|Comments Off on Kite Pharma case study